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Background: Patient-reported outcomes (PROs) may provide valuable information to clinicians and patients when
choosing initial antiretroviral therapy.
Objective: To identify and classify PRO instruments used to measure treatment effects in clinical trials evaluating
NNRTIs.
Methods: We conducted a structured literature review using PubMed to identify NNRTI trials published from March
2003 to February 2013. Studies identified--based on disease, instrument, PRO, and NNRTI medication terms were
reviewed--to identify PRO instruments. Domains measured within each instrument were recorded to understand
key areas of interest in NNRTIs.
Results: Of 189 articles reviewed, 27 validated instruments were administered in 26 unique trials, with a mean of
1.9 instruments (median: 1; range: 1–7) per trial. The Medical Outcomes Study HIV Health Survey (MOS-HIV) was the
most commonly used instrument (n = 8 trials). Seventeen trials (65%) included at least one multidimensional health-
related quality of life (HRQL) instrument (HIV-targeted, n = 11; general, n = 8). Other validated instruments measured
sleep (n = 5), depression (n = 5), anxiety (n = 4), psychiatric symptoms (n = 2), beliefs about HIV medications (n = 2),
HIV symptoms (n = 1), and stress (n = 1).
Conclusions: Although review of recent NNRTI trials suggests a lack of consensus on the optimal PRO instruments,
a typical battery is comprised of a multidimensional HRQL measure coupled with one or more symptom measures.
Further work is needed to clarify advantages and disadvantages of using specific PRO instruments to measure
relevant constructs and to identify the most useful batteries of instruments for NNRTI trials.
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The primary goal of HIV therapy is to increase disease-
free survival and improve health-related quality of life
(HRQL) by containing viral replication, avoiding drug re-
sistance, and boosting immunologic function by restoring
CD4 count [1,2]. The United States Department of Health
and Human Services (DHHS) has recommended several
preferred and alternative initial highly active antiretroviral
therapy (HAART) regimens which have comparable* Correspondence: kristy.hanson@ubc.com
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reproduction in any medium, provided the orefficacy, but different pharmacokinetic or pharmacody-
namic properties. DHHS further recommends tailoring
the HAART regimen to the patient--based on expected
side effects, convenience, comorbidities, potential drug in-
teractions, and results of any pre-treatment genotypic
drug-resistance testing--to optimize medication adherence
and improve long-term treatment success [3]. Since some
of these constructs must be measured from the patient
perspective, it is important to consider patient-reported
outcomes (PROs) when selecting initial antiretroviral
therapy.
A PRO is defined as any report of the status of a patient’s
health condition that comes directly from the patiental Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ician or anyone else [4]. In clinical trials, PRO instruments
can be used to measure the effect of a medical interven-
tion on one or more concepts – such as symptoms, func-
tioning, severity of disease, or HRQL. Given the
armamentarium of potent HAART regimens available
today, HIV infection has been transformed from a ter-
minal illness into a chronic condition. As such, there is a
strong case for evaluating the impact of antiretroviral ther-
apies on broader aspects of patient’s lives, including psy-
chological health and emotional adjustment. The
majority of published comparative treatment studies that
include PROs are limited to comparing differences be-
tween protease inhibitor (PI) and non-nucleoside reverse
transcriptase inhibitor (NNRTI)-based regimens. This may
be due in part to the fact that for several years, treatment
guidelines have recommended initiating HAART with two
NRTIs plus either an NNRTI or a boosted PI [5,6]. How-
ever, this broad comparison may miss important distinc-
tions among regimens that are related to within-class PRO
differences.
Although five NNRTIs have received Food and Drug
Administration (FDA) approval to date, European AIDS
Clinical Society (EACS) and DHHS treatment guidelines
recommend efavirenz (EFV) as the NNRTI of choice to be
used in most treatment-naïve HIV-infected adults initiating
NNRTI-based therapy [3,6]. Other recommended NNRTIs
include nevirapine (NVP) and rilpivirine (RVP). In the ab-
sence of head-to-head comparative clinical trials demon-
strating clinical superiority of one NNRTI over another,
PROs become an important tool for identifying treatment
differences and informing treatment choices. A necessary
first step to understanding differences among specific
NNRTIs is to examine the PRO instruments being used
in clinical trials and the aspects of health they measure.
Therefore, the purpose of this study was to identify and
classify PRO instruments used to measure treatment ef-
fects in clinical trials evaluating NNRTIs.
Methods
Literature search
An electronic search using PubMed was conducted evalu-
ating studies published from March 2003 to February
2013. Our search strategy included a combination of Med-
ical Subject Headings (MeSH) terms for HIV [HIV OR
HIV infections], MeSH terms associated with PROs/in-
struments [questionnaires OR interviews as topic OR
quality of life OR patient satisfaction OR self-evaluation
programs], Substance Names of NNRTIs [efavirenz OR
nevirapine OR delavirdine OR etravirine OR rilpivirine
OR efavirenz, emtricitabine, tenofovir disoproxil fumarate
drug combination], and clinical trial Publication Types
[clinical trial OR clinical trial, phase IV OR clinical trial,
phase III OR clinical trial, phase II OR controlled clinicaltrial OR randomized controlled trial]. A complete list of
all search terms used, including terms used in title/ab-
stract searches, is shown in Additional file 1. We limited
our search to articles written in English with abstracts
available. In addition to the PubMed search, we conducted
a manual search of the bibliographies of the electronically-
identified primary studies and review articles.
Study selection
The inclusion and exclusion criteria for studies to be
considered in our systematic review were established
prior to conducting the literature search. All identified
articles were independently screened by two authors. Pa-
pers included in our review reported on clinical trials
evaluating NNRTI-based treatment regimens in HIV-
infected adults and administering at least one validated
PRO instrument. Full-text articles of study abstracts
which appeared to administer a PRO instrument were
reviewed for the name and citation of the validated in-
strument. Reviews, editorials, animal studies, and those
reporting results of children were excluded from our
analysis.
Data extraction
Data collected from each study included population char-
acteristics, study design, study objective, treatments, and
PRO instruments administered. We categorized each vali-
dated PRO instrument by type (e.g., HRQL, symptoms) to
understand key domains of interest in NNRTI-based ther-
apy. We also assessed the number of items, scoring, and
dimensions/concepts measured by each instrument. For
the most commonly used instruments, PRO-related data
(e.g., baseline and follow-up scores, effect sizes, and sig-
nificance values) were extracted from the studies, as avail-
able. The most commonly used PROs and study results
were described.
Results
A total of 189 articles were identified by the literature
search and bibliography review. Most articles were ex-
cluded because they did not include a validated PRO in-
strument (n = 111). Articles were also excluded for one or
more of the following reasons: review articles (n = 33), du-
plicate studies (n = 18), evaluated HIV therapies in chil-
dren (n = 5), or did not evaluate NNRTI-based regimens
(n = 13). Twenty-six unique clinical trials met all selection
criteria and were included in the review.
Table 1 presents the characteristics of the 26 clinical
trials. Almost all were randomized controlled trials (n =
20). The number of PRO instruments per study ranged
from 1 to 7, with most studies including only one (54%)
or two (23%) validated PRO instruments. In addition to
validated PRO instruments, eight of the 26 trials (31%)
used non-validated and study-specific instruments to
Table 1 Characteristics of included studies










To assess the effect of cyproheptadine
in prevention of neuropsychiatric adverse


















Bucciardini (2012) [8] Treatment-experienced patients
with treatment failure, resistance,
or intolerance with HAART (2
NRTIs + NNRTI or PI) (n = 101)
Prospective, observational
study (sub-set of ISS-NIA
study)
To evaluate rates and determinants of
virological failure in triple-class experienced
patients receiving raltegravir-based regimens






ISSQoL HRQL: General (1)
Lake (2012) [9] HIV-infected women with central
adiposity and viral suppression
on NNRTI- or PI-based HAART
(n = 37)
RCT (open-label) To evaluate effects of a switch from a PI or
NNRTI to RAL on adipose tissue volume and
metabolic changes
1) Immediate switch of








2) Delayed switch (at 24
weeks) of PI or NNRTI to
RAL (continuing prior
NRTI backbone)
Mosam (2012) [10] Treatment-naïve patients with
HIV-associated Kaposi sarcoma
(n = 112)
RCT (open-label) To compare HRQL between 2 ARV regimens:
ZDV/3TC/NFV versus ZDV/3TC/NVP
1) d4T/3TC/NVP EORTC QLQ-30 HRQL: General (1)
2) d4T/3TC/NVP +
chemotherapy
Cooper (2011) [11] Treatment-experienced patients
on stable ZDV/3TC/EFV regimen
(n = 234)
RCT (open-label) To assess the effect of switching ZDV/3TC/EFV
to TDF/FTC/EFV on adherence, beliefs about
ARV therapy and HQRL
1) Continue ZDV/3TC/
EFV twice daily






2) Switch to TDF/FTC/
EFV once daily
SF-12 (v2)
Nguyen (2011) [12] Stable EFV-containing HAART
regimen (n = 53)
RCT (double-blind,
cross-over)
To investigate the effect of replacing EFV with
RAL on patient preference, sleep quality,
daytime sleepiness, anxiety, and lipid levels
1) Continue EFV-
containing regimen, then
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2) RAL + prior NRTI
backbone, then switch






Nguyen (2011) [13] Stable EFV-containing HAART
regimen (n = 58)
RCT (double-blind,
cross-over)
To investigate the effect of replacing EFV with
ETR on patient preference, sleep, anxiety, and
lipid levels
1) EFV-based therapy ESS Sleep (3)








Campo (2010) [14] PI-based HAART regimen without
history of virological failure
(n = 262)
RCT (open-label) To evaluate the efficacy, safety and PROs of
regimen switching to EFV-based HAART
1) Switch to EFV/3TC/
ddI
FAHI HRQL: HIV (1)








Cella (2010) [15] Stable, but virologically failing
ARV regimen (n = 1,203)
RCT (pooled analysis of
DUET-1 and DUET-2)
To study the effects of etravirine versus
placebo on the HRQL of HIV-infected patients
1) ETR 200 mg twice-
daily3
FAHI HRQL: HIV (1)
2) Placebo3
Cooper (2010)] [16] HIV-infected, treatment-naïve
patients (n = 87)
RCT (open-label) To determine the impact of once-nightly
versus twice-daily dosing and beliefs about


















To evaluate the long-term efficacy, safety,
adherence, and HRQL of once-daily EFV-
based HAART
1) ZDV/3TC + MVC 300
mg twice daily
HIV-SI/SDM HIV symptoms (1)
2) ZDV/3TC + MVC 600
mg once daily




PI- or NNRTI-based ARV regimen
with virologic suppression
(n = 300)
RCT (open-label) To evaluate the therapeutic switch to a
single-tablet formulation of EFV/FTC/TDF
among virologically suppressed, HIV-infected
adults
1) EFV/FTC/TDF SF-36 (v2) HRQL: General (1)
2) Continue baseline
ARVs (PI- or NNRTI-
based)
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Potard (2010) [21] Treatment experienced, NNRTI-na
ïve (n = 239)
Prospective,
observational study
To assess changes in HRQL after switching to
an NNRTI-containing regimen
1) EFV-based therapy HADS Anxiety/
depression (1)
2) NVP-based therapy HIV-SI/SDM
WHOQOL-HIV HIV symptoms (1)
BREF HRQL: General (2)
SF-12 (v2)
Clifford (2009) [22] Treatment-naïve; study reports
long-term follow-up of patients
after unblinding of the AZT/3TC/
ABC treatment arm (n = 303)
RCT (secondary analysis
of A5095)
To evaluate the long-term impact of EFV-
based regimens on neuropsychological
performance
1) AZT/3TC/EFV CES-D Depression (1)






Patients scheduled to receive an
EFV-containing treatment plus 2
NRTIs (n = 114)
RCT (double-blind) To determine if starting EFV in a stepwise
dose schedule decreases EFV-related














To evaluate the long-term efficacy, safety,




MOS-HIV HRQL: HIV (1)





To evaluate the long-term efficacy, safety,




MOS-HIV HRQL: HIV (1)
Boyle (2008) [25] Treatment-experienced patients
on stable twice-daily or more
frequent HAART (n = 320)
RCT (open-label) To evaluate the effect of regimen
simplification on maintenance of virologic
suppression and treatment adherence
1) Continue baseline
ARVs (BID + dosing)
FAHI HRQL: HIV (1)
IIRS HRQL: General (1)






DeJesus (2008) [26] Stable regimen of fixed-dose
AZT/3TC with EFV, experiencing
AZT/3TC-related adverse effects
or who might benefit from a
simplified regimen (n = 402)
Prospective, single-arm
trial
To evaluate the impact of switching from
twice-daily AZT/3TC to once-daily TDF/FTC
with EFV)
1) Switch from twice-
daily AZT/3TC to once-
daily TDF/FTC with EFV
SF-36 (v2) HRQL: General (1)
HIV-SI/SDM HIV symptoms (1)
Treatment
satisfaction
Bucciardini (2007) [27] Treatment-naïve (n = 139) RCT (secondary analysis
of INITIO-QoL data)
To detect differences in patient’s HRQL
among the 3 study treatment groups in the
INITIO trial
1) ddI/d4T/EFV MOS-HIV HRQL: HIV (1)
2) ddI/d4T/NFV
3) ddI/d4T/EFV/NFV
Lafaurie (2008) [28] NNRTI-naïve, receiving stable
HAART consisting of at least 1 PI,




To assess if patients who have tolerated long-





MOS-HIV HRQL: HIV (1)
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Journot (2006) [29] NNRTI-naïve, receiving
unchanged HAART for ≥6
months consisting of at least 1 PI




To determine whether EFV use is associated
with a higher incidence of depressive











receiving d4T/3TC/EFV or ZDV/
3TC/EFV (n = 43)
RCT (open-label) To assess whether virologically controlled HIV-
1-infected individuals switched from a twice-
daily antiretroviral regimen to a once-daily
regimen demonstrate improved adherence





MOS-HIV HRQL: HIV (1)
2) Switch to once-daily
d4T(PRC)/3TC/EFV
Casado (2004) [31] Treatment-naïve; subset of





To compare HRQL between 2 ARV regimens:
ZDV/3TC/NFV versus ZDV/3TC/NVP
1) ZDV/3TC/NFV MOS-HIV HRQL: HIV (1)
2) ZDV/3TC/NVP





To explore the long-term safety, and the
virological and immunological efficacy of
once-daily ddI/TDF/NVP in previously HAART-
experienced subjects with long-lasting viral
suppression
1) Continue twice-daily
ARV therapy (PI- or
NNRTI-based)
MOS-HIV HRQL: HIV (1)
2) Switch to once-daily
ddI/TDF/NVP
van Leth (2004) [33] Treatment-naïve; subset of
patients with HRQL data in




To investigate whether these differences in
the safety profiles of EFV and NVP translates
into differences in HRQL
1) d4T/3TC/EFV MOS-HIV HRQL: HIV (1)
2) d4T/3TC/NVP
3) d4T/3TC/EFV/NVP
Abbreviations: 3TC lamivudine, ABC abacavir, ACTG AIDS Clinical Trials Group, ARV antiretroviral, AZT zidovudine, BDI-II Beck Depression Inventory, second edition, BMQ-ART Beliefs about Medicines Questionnaire,
adapted for antiretroviral therapy, CES-D Centre for Epidemiologic Studies-Depression scale, d4T stavudine, DASS21 Depression Anxiety and Stress Scale-short version, ddI didanosine, EFV efavirenz, EORTC QLQ-30
European Organization for Research and Treatment of Cancer Quality of Lfe Questionnaire, ESS Epworth Sleep Score, ETR etravirine, FAHI Functional Assessment of HIV Infection, FTC emtricitabine, GSQS Groningen
Sleep Quality Score, HAART highly-active antiretroviral therapy, HADS Hospital Anxiety and Depression Scale, HAM-A Hamilton Anxiety Rating Scale, HAM-D Hamilton Depression Rating Scale, HIV-SI HIV Symptom
Index, HRQL health-related quality of life, IIRS Illness Intrusiveness Rating Scale, ISSQoL Istituto Superiore di Sanità Quality of Life, MOS-HIV Medical Outcomes Study HIV health survey, NFV nelfinavir, NNRTI non-
nucleoside reverse transcriptase inhibitor, NRTI nucleoside/nucleotide reverse transcriptase inhibitor, NVP nevirapine, PANSI Positive and Negative Syndrome Scale, PANSS Positive and Negative Suicide Ideation, PI
protease inhibitor, PRO patient-reported outcome, PSQI Pittsburgh Sleep Quality Index, RCT randomized controlled trial, SCL-90 Symptom Checklist-90, SDM Symptom Distress Module, SF-12 MOS 12-item short-form
health survey, SF-36 MOS 36-item short-form health survey, SSS Stanford Sleepiness Scale, STAI State-Trait Anxiety Inventory, TDF tenofovir, WHOQOL-HIV BREF World Health Organization Quality of Life-HIV,
short version.
1All subjects are HIV-infected adults; 2Excludes patient-reported adherence-only instruments (e.g., ACTG Adherence Questionnaire); 3Both groups received darunavir/ritonavir (DRV/r) and an investigator-selected
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http://www.hqlo.com/content/11/1/164measure such aspects as treatment preference, treatment
satisfaction, perceived ease of regimen, and neuropsychi-
atric symptoms.
The PRO instruments used corresponded to each study’s
primary objective (e.g., HRQL studies used general or HIV-
targeted HRQL instruments, a study to compare depressive
symptoms in patients taking EFV- versus PI-based re-
gimens used the CES-D, a depression-specific PRO in-
strument, etc.). Most studies utilizing a generic HRQL
instrument (e.g., SF-36, SF-12) also included either an HIV-
targeted HRQL or symptom instrument [11,14,19-21,25].
Overall, 27 validated PRO instruments were identified.
Six of the instruments the Medical Outcomes Study
HIV Health Survey (MOS-HIV), Functional Assessment
of HIV Infection (FAHI), World Health Organization
Quality of Life HIV BREF (WHOQOL-HIV BREF), HIV
Symptom Index (HIV-SI)/AIDS Clinical Trials Group
Symptom Distress Module (SDM), Beliefs about Medicines
Questionnaire-ART version (BMQ-ART) and HAART
Intrusiveness Scale were developed specifically to be ad-
ministered in the HIV population. The remaining instru-
ments were either generic HRQL instruments or general
symptom-specific instruments.
Characteristics of the PRO instruments, including the
number of items, concepts measured, and scoring method,
are presented in Table 2. Based on review of the concepts
measured by the PROs, key areas of interest measured by
PROs in NNRTI clinical trials include general and HIV-
targeted HRQL (typically comprised of physical, emotional,
social, and functioning domains), HIV-related symptoms
(including anxiety, depression, sleep, psychiatric symp-
toms, and stress), and medication-related beliefs.
Table 3 provides a summary of the validated PRO instru-
ments, categorized by instrument type, utilized in the 26
studies. The MOS-HIV, administered in 8 clinical trials, was
the most commonly used PRO instrument. Table 4 presents
PRO results for all PRO instruments used in three or more
studies: the MOS-HIV, FAHI, HIV-SI/SDM, and CES-D.
Discussion
Evaluation of PROs during clinical practice, as well as in
clinical research, enhances understanding of disease im-
pact and effect of treatment on that disease impact.
Thus, PRO assessment should be recognized by patients
and their physicians, as well as by payers and health
technology assessment authorities, as improving the
knowledge base on which to base health care decision
making, and ultimately to improve patient health. This
study found that the key areas of PRO interest in clinical
trials of NNRTI-based therapy are HRQL (general or
HIV-targeted, and typically comprised of physical, emo-
tional, social and functioning domains), HIV symptoms,
sleep, and psychiatric symptoms, including anxiety, de-
pression, stress, and medication beliefs. A variety ofinstruments were used to measure these dimensions.
The only instruments used in three or more clinical tri-
als within the past ten years were the MOS-HIV, FAHI,
and CES-D.
Overall, although we were able to identify important
concepts measured in NNRTI studies based on the conver-
gence of PRO instrument types (e.g., HRQL, HIV symp-
toms, anxiety, depression), there was a noticeable lack of
consensus among studies on specific instruments utilized
to measure each concept. For example, of five generic
HRQL instruments identified, none were used in more
than two studies.
To our knowledge, this is the first study to systematic-
ally identify and categorize PRO instruments used specif-
ically in NNRTI clinical trials. Clinical trials commonly
use more than one PRO instrument. Although each PRO
instrument may be able to contribute valuable informa-
tion, it is important to carefully weigh the advantages and
disadvantages of each instrument, especially related to its
sensitivity and specificity to capture the patient factors of
greatest importance. This is important both maximize the
chances of detecting important differences between treat-
ments, as well as to limit patient response burden.
A multidimensional generic HRQL instrument, such as
the SF-36 or EQ-5D, is useful because it comprehensively
measures HRQL and has norm-based scoring which can
be used to compare the study population with others. Fur-
thermore, it can be used in population-wide decision mak-
ing by providing data on quality of life weights or utilities
for inclusion in cost-effectiveness and cost-utility analyses.
For example, this can be done directly (e.g., using the EQ-
5D) or indirectly (e.g., by deriving SF-6D utility weights
from the SF-36). However, a disadvantage of using generic
measures is that they may be less sensitive or responsive
to small but important changes that occur due to changes
in disease status, adverse events, or to treatment effect,
and which may occur over the typical timeframe of a ran-
domized control trial.
HIV-targeted HRQL instruments, such as the MOS-
HIV, FAHI, and WHOQOL-HIV BREF, were each devel-
oped by revising, at least in part, generic HRQL
instruments (the SF-20, Functional Assessment of Can-
cer Therapy-General [FACT-G], and WHOQOL-BREF,
respectively) with input from HIV-infected patients and
HIV-treatment providers to ensure more complete
coverage of concepts specific to HIV infection. Each in-
strument demonstrates excellent psychometric proper-
ties in the HIV population. In contrast to the generic
HRQL instruments, a disadvantage of HIV-targeted in-
struments is that they do not provide a means for
estimating utilities, which can be useful in clinical-
economic modeling considered by health technology as-
sessment authorities and others focused on population
health.













19 HAART necessity scale (beliefs about personal need for HAART for
controlling HIV, maintaining their health, preventing illness), HAART







3 Belly size, belly image distress, belly profile X
CES-D Psychiatric
symptoms2
20 Frequency and severity of depression symptoms X
DASS21 Psychiatric
symptoms2,3,4
21 Depression, anxiety, stress X
EORTC QLQ-
30
HRQL (general) 30 6 functioning scales (physical, role, cognitive, emotional, social, global
QOL), 9 symptom scales/items (fatigue, pain, nausea and vomiting,
dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, financial
impact)
X
ESS Sleep5 8 Rates chances of dozing during the daytime in 8 situations X
FAHI HRQL (HIV-
targeted)
47 Physical well-being, functional and global well-being, emotional well-
being/living with HIV, social well-being, cognitive functioning
X X







12 Degree to which ART is perceived to interfere with aspects of daily life




14 Anxiety, depression X
HAM-A Psychiatric
symptoms3
14 Severity of anxiety X
HAM-D Psychiatric
symptoms2
17 Severity of depression X
HIV-SI / SDM HIV symptoms 20 HIV- or treatment-related symptoms (e.g., fatigue, dizziness, nausea,
depression, anxiety)
X7 X
IIRS HRQL (general) 13 Relationships and personal development, intimacy, instrumental X X
ISSQoL HRQL (HIV-
targeted)
62 QOL core (satisfaction with QOL, physical well-being, role well-being,
social functioning, depression/anxiety, energy/vitality, health distress,
cognitive functioning, sexual life), Additional important areas (social





35 General health perceptions, physical functioning, role functioning, social
functioning, pain, energy/fatigue, health distress, mental health, cognitive
functioning, and quality of life
X X1 X
OSQ Sleep6 13 Subjective sleep quality, somnolence, insomnia, nightmares X
PANSI Psychiatric
symptoms
14 Positive suicidal ideation, negative suicidal ideation X
PANSS Psychiatric
symptoms
30 Positive items (e.g., delusions, hallucinations), Negative items (e.g.,
blunted affect, emotional withdrawal), General Psychopathology (e.g.,
anxiety, depression, disorientation)
X X
PSQI Sleep6 19 Subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency,







12 Distress arising from perceptions of bodily dysfunction, such as
cardiovascular, gastrointestinal, respiratory, and autonomic symptoms
X
SF-12 HRQL (general) 12 Physical functioning, role physical, bodily pain, general health, vitality,
social functioning, role emotional, mental health
X X1
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Table 2 Characteristics of identified PRO measures (Continued)
SF-36 HRQL (general) 36 Physical functioning, role-physical, bodily pain, general health, vitality,
social functioning, role-emotional, mental health, reported health
transition
X X1
SSS Sleep5 1 Subjects select 1 statement to best describe typical sleepiness at work









31 Physical, psychological, level of independence, social relationships,
environment, spirituality
X
Abbreviations: BDI-II Beck Depression Inventory, second edition, BMQ-ART Beliefs about Medicines Questionnaire, adapted for antiretroviral therapy, CES-D Centers
for Epidemiological Studies-Depression, DASS21 Depression Anxiety and Stress Scale, short version, EORTC QLQ-30 European Organization for Research and
Treatment of Cancer Quality of Life Questionnaire, ESS Epworth Sleep Score, FAHI Functional Assessment of HIV Infection, GSQS Groningen Sleep Quality Score,
HAART Highly Active Antiretroviral Therapy, HADS Hospital Anxiety and Depression Scale, HAM-A Hamilton Anxiety Rating Scale, HAM-D Hamilton Depression
Rating Scale, HIV-SI HIV Symptom Index, HRQL health-related quality of life, IIRS Illness Intrusiveness Rating Scale, ISSQoL Istituto Superiore di Sanità Quality of Life,
MOS-HIV Medical Outcomes Study-HIV, OSQ Oviedo Sleep Questionnaire, PANSI Positive and Negative Syndrome Scale, PANSS Positive and Negative Suicide
Ideation, PSQI Pittsburgh Sleep Quality Index, SCL-90 Symptom Checklist-90, SDM Symptom Distress Module, SF-12 MOS 12-item short-form health survey, SF-36
MOS 36-item short-form health survey, SSS Stanford Sleepiness Scale, STAI State-Trait Anxiety Index, WHOQOL-HIV BREF World Health Organization Quality of
Life-HIV, short version.
1Physical health and mental health summary scores; 2Depression; 3Anxiety; 4Stress; 5Daytime sleepiness; 6Sleep quality; 7Symptom count and symptom
bother count.
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sidered to be the gold standard in clinical research.
However, a generic symptom-specific instrument may be
more appropriate when the primary or secondary study
objective is to measure a specific symptom; such
symptom-specific instruments generally measure the
symptom and different attributes and impacts with mul-
tiple items, thus providing greater insights into the ex-
tent and effect of the measure.
More than half of the articles initially identified
were excluded from our review because the abstract
did not report use of a PRO instrument. However,
this likely underestimates of the frequency of admin-
istration of PRO instruments in clinical trials for
two reasons: 1) we used an extensive list of search
terms in order to capture as many validated PRO in-
struments as possible, and consequently identified
non-relevant articles, and 2) PROs are generally sec-
ondary endpoints in clinical trials; as such, they may
not be mentioned in the study abstract and com-
monly are reported in separate publications. Since
we did not review the full text of excluded articles,
we do not know if the excluded studies were unique
clinical trials or secondary publications of identified
trials.
There are several limitations to our study that should
be noted. First, our review excluded questionnaires
measuring adherence because we were only interested in
patient-reported measures of treatment effects. However,
it should be noted that the HIV-SI/SDM is a component
of the ACTG Adherence Questionnaire, a validated in-
strument developed by the AIDS Clinical Trial Group.
Although our review excluded studies which mentioned
only adherence and no additional patient-reported mea-
sures in the study abstract, based on abstract review weidentified two studies which used the ACTG Adherence
Questionnaire [34,35]. It is possible that there are add-
itional studies which used the ACTG Adherence Ques-
tionnaire as the adherence measure, and therefore also
measured HIV symptoms with the HIV-SI/SDM, which
were not included in our literature review. Secondly, our
review only evaluated studies using validated PRO in-
struments. However, some studies use study-specific in-
struments which are based on one or more validated
instruments. For example, studies by Santos et al. [36]
and Martinez-Picado et al. [37] used modified versions
of the MOS-HIV and thus were not fully evaluated in
our review. Finally, our review focused on PRO instru-
ments included in prospective clinical trials of NNRTIs.
It should be noted that there are clinical research net-
works, such as the Centers for AIDS Research Network
of Integrated Clinical Systems (CNICS) which allow for
retrospective review of PROs measured during routine
medical visits [38]. PRO instruments used at these clin-
ical sites include the Patient Health Questionnaire
(PHQ) for depression and anxiety, HIV-SI for symptom
burden, and EQ-5D for HRQL, among others. For ex-
ample, a study by Kozak et al. [39] used reports from
the Patient Health Questionnaire depression scale
(PHQ-9) and the Alcohol, Smoking and Substance In-
volvement Screening Test (ASSIST) to demonstrate that
current substance abuse (odds ratio [OR], 2.78; 95% con-
fidence interval [CI], 1.33–5.81) and current depression
(OR, 1.93; 95% CI, 1.12–3.33) were associated with poor
antiretroviral adherence in HIV patients. Additional re-
search, including review of NNRTI studies published in
non-English languages and retrospective analyses of
PROs collected during usual medical care visits, should
be conducted and could build on the findings presented
here.
Table 3 PRO instruments identified in trials with NNRTIs
Instrument type and name Study count





Illness Intrusiveness Rating Scale (IIRS) 2
Istituto Superiore di Sanità Quality of Life (ISSQoL) 1
HIV-targeted
Medical Outcomes Study HIV (MOS-HIV) 81
Functional Assessment of HIV Infection (FAHI) 3
World Health Organization Quality of Life (WHOQOL)-HIV BREF 1
Instruments measuring symptoms
General HIV symptoms
HIV Symptom Index (HIV-SI) /AIDS Clinical Trials Group Symptom Distress Module (SDM) 32
Sleep
Pittsburgh Sleep Quality Index (PSQI) 2
Epworth Sleep Score (ESS) 2
Stanford Sleepiness Scale (SSS) 2
Groningen Sleep Quality Score (GSQS) 2
Oviedo Sleep Questionnaire (OSQ) 1
Anxiety (only)
Hamilton Anxiety Rating Scale (HAM-A) 1
State-Trait Anxiety Inventory for Adults (STAI) 1
Depression (only)
Centers for Epidemiological Studies-Depression (CES-D) 3
Beck Depression Inventory-2nd edition (BDI-II) 1
Hamilton Depression Rating Scale (HAM-D) 1
Anxiety and depression (only)
Hospital Anxiety and Depression Scale (HADS) 1
Anxiety, depression, and stress
Depression Anxiety and Stress Scale-short version (DASS21) 1
Psychiatric symptoms
Positive and Negative Syndrome Scale (PANSS) 1
Positive and Negative Suicide Ideation (PANSI) 1
Symptom Checklist-90 (SCL-90) - Somatization Subscale 1
Body Image Impact scale 1
Instruments measuring beliefs about medications
Beliefs about Medicines Questionnaire-ART version (BMQ-ART) 2
HAART Intrusiveness Scale 2
12 additional studies used modified versions of the MOS-HIV; 22 additional studies used the ACTG Adherence Questionnaire, which contains the HIV-SI/SDM.
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Review of recently published NNRTI clinical trials suggests
a lack of consensus on the optimal PRO instruments to in-
clude to measure key domains. Overall, a typical battery ofinstruments is comprised of a multidimensional measure
of HRQL (either HIV-targeted or generic) coupled with
one or more symptom measures. Further work is needed
to clarify the advantages and disadvantages of using various
Table 4 PRO results of commonly used instruments
Study
reference






Summary of PRO results
Instrument: Centre for Epidemiologic Studies – Depression Scale (CES-D)
Lake (2012)
[9]
Immediate switch of PI or
NNRTI to RAL (continuing
prior NRTI backbone)
Depression NR 24 weeks, NR N/A ● The CES-D was administered at 0, 4,
8, 12, 18, and 24 weeks, but patient-
reported depression scores were not
reported in this study.
Delayed switch (at 24 weeks)
of PI or NNRTI to RAL
(continuing prior NRTI
backbone)
Depression NR 24 weeks, NR N/A
Clifford
(2009) [22]
ZDV/3TC/EFV Depression 12.2 (10.5) 184 weeks1, 10.1a 0.20 ● In participants who continued EFV-
based regimens, neuropsychological
performance improvement from
baseline was maintained over 3 years.
ZDV/3TC/ABC Depression 11.8 (10.5) 184 weeks1, 10.4 0.13 ● There was statistically significant
decrease in depression symptoms over
the course of the study with the
median score decline of 1.0 (P = 0.03).
Various regimens (± EFV) Depression 13.3 (11.1) 184 weeks1, 16.6 −0.30 ● In the long-term EFV-treated group,
the percent with CES-D scores >16
declined from 34.1% to 22.3% over the
duration of the study.
ZDV/3TC/ABC initially, then
EFV added (± ABC)
Depression 13.8 (12.5) 184 weeks1, 8.6 0.42
Journot
(2006) [29]
PI-based therapy Depression2 23% 48 weeks, 25% N/A ● Proportion of patients with
depression was approximately 24% at
BL and remained stable during the 48
week follow-up with no difference
between treatment arms, P = 0.65).
EFV-based therapy Depression2 25% 48 weeks, 24% N/A
36 months, 24% N/A
● Patients with a history of depression
experienced depressive symptoms
more frequently than those without
such history (53% and 22% at week 48,
respectively; P = 0.03).
Instrument: Functional Assessment of HIV Infection (FAHI)
Campo
(2010) [14]
Switch to EFV/3TC/ddI Total Score 130 48 weeks, 134a N/A ● In the overall patient population,
FAHI total score increased significantly
from BL to week 48 (P < 0.001) and at
every other time point; changes in
total score were associated with
improvements in the physical and
emotional well-being domains
(P < 0.001 for both).
Switch PI to EFV (continuing
prior NRTIs)




ETR 200 mg twice-daily3 Total Score 121.7 (23.7)5 24 weeks, 127.3a,b 0.21 ● The change in physical well-being,
emotional well-being/living with HIV
and total scores from BL to Week 24
were statistically different from zero for
both groups, with statistically
significant greater improvements
observed in the ETR group.
Placebo3 Total Score 120.9 (26.7)5 24 weeks, 124.0a,b 0.11
Boyle (2008)
[25]
Continue BL ARVs (BID+
dosing)
Total Score 130.4 48 weeks, NR N/A ● A small improvement (5% or less) for
the emotional well-being and a small
reduction (9% or less) for functional
and global well-being were observed
at some time points in both arms;
however, these were not considered
clinically relevant, as the effect sizes
were small.
Switch to once-daily d4T/
3TC/EFV
Total Score 131.4 48 weeks, NR N/A ● No significant differences observed
between arms.
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Instrument: HIV Symptom Index / Symptom Distress Module (HIV-SI / SDM)
Hodder
(2010) [19]
EFV/FTC/TDF Dizziness 28% 4 weeks, 39%a,b N/A ● Simplification from PI-based or NNRTI-
based regimens to EFV/FTC/TDF was
associated with transient worsening or
emergence of dizziness and sustained
improvements in several other HIV-
related symptoms: diarrhea or loose
bowel movements; bloating, pain or gas
in the stomach, changes in body
appearance, and problems having sex.
48 weeks, 28% N/A
Remain on BL antiretroviral
regimen
Dizziness 27% 4 weeks, 25%b N/A
48 weeks, 28% N/A
Potard
(2010) [21]
EFV- or NVP-based therapy Symptom
Count
11.9 (9.1) 12 months, 9.0a 0.32 ● Overall, there was a small
improvement in HIV symptoms at 1




7.7 (5.9) 12 months, 6.0a 0.29 ● An initial difference between groups
in mean change in other symptoms,
bothersome symptoms, and other
bothersome symptoms observed at 1




ZDV/3TC +MVC 300 mg
twice dailyZDV/3TC + MVC
600 mg once dailyZDV/3TC +







96 weeks, NR N/A ● This study assessed the cross-cultural
validity of the HIV-SI using pre-ARV
treatment cross-sectional data of the
MERIT trial.
● Statistically significant differential
item functioning between cultural
groups was observed for 4 items:








96 weeks, NR N/A ● The authors concluded that the
absence of meaningful explanations
for statistically significant differences
between cultural groups supports the
cross-cultural validity of the HIV-SI
versions used in the MERIT trial.
DeJesus
(2008) [26]
Switch from twice-daily AZT/




NR 24 weeks, NR N/A ● Significant differences were
observed in the percentage of patients
reporting the absence of the symptom
at Week 24 compared to BL for 17 of




NR 24 weeks, NR N/A ● Compared to BL, significantly more
patients reported the absence of
fatigue, absence of nausea and
vomiting, absence of diarrhea, and
absence of headache.
Instrument: Medical Outcomes Study HIV health survey (MOS-HIV)
Jayaweera
(2009) [24]
ddI/3TC/EFV once-daily Total Score 874 96 weeks, 924 N/A ● The overall MOS-HIV QoL score,
which is the sum of all individual MOS-
HIV scores (range: 0 to 1,100),
significantly improved from BL (874) to
Week 96 (924; P < 0.05).
Jayaweera
(2009) [24]
d4T/3TC/EFV once-daily Total Score 832 12 weeks, 880 N/A ● The overall MOS-HIV QoL score
significantly improved from BL (832) to
Week 12 (880; P < 0.05).
Lafaurie
(2008) [28]
PI-containing regimen PHS 56.5 (50.0-61.8)3 48 weeks, -1.044 0.24 ● The mean change from BL to week
48 in the PCS and MCS were −1.04
and +0.0 in the maintenance arm
and −1.76 and +1.01 in the switch
arm, respectively (P = 0.57 and 0.42).
MHS 40.2 (33.8-45.3)3 48 weeks, 0.004 0.00
EFV/ddI/FTC PHS 57.4 (51.5-60.4)3 48 weeks, -1.764 0.53 ● Specific items such as physical
functioning, social functioning, and
emotional functioning remained
unchanged in both treatment groups
during follow-up.
MHS 38.3 (33.4-43.6)3 48 weeks, 1.014 −0.27
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Bucciardini
(2007) [27]
ddI/d4T/EFV PHS 50 (11) 3 years, 54.9 −0.45 ● Similar results reported for follow-up
at years 1 and 2 (data not shown).
MHS 49 (10) 3 years, 49.5 −0.05
ddI/d4T/NFV PHS 46 (13) 3 years, 50.9 −0.38 ● During follow-up, an increase of PHS
score was observed in all treatment
arms (NS).MHS 48 (10) 3 years, 53.5 −0.55
ddI/d4T/EFV/NFV PHS 48 (12) 3 years, 50.0 −0.17 ● The MHS score of both NNRTI- and
PI-based 3-drug regimens showed a
trend toward improvement but
remained substantially unchanged
with the four-drug combination.




of d4T(IR)/3TC/EFV or ZDV/
3TC/EFV
Total Score NR 24 weeks, NR N/A ● There were no significant differences in
quality of life between the IR and PRC
arms based on overall (sum of 11
domains) change from BL to week 24.
Cognitive
Function
NR 24 weeks, NRa N/A ● Both arms showed significant
improvement in the cognitive function
domain (P < 0.001) during the course
of the study, based on BL cognitive
scores at weeks 12 and 24.
Switch to once-daily d4T
(PRC)/3TC/EFV




NR 24 weeks, NRa N/A
Casado
(2004) [31]
ZDV/3TC/NFV PHS 54.16 (8.97) 12 months, 52.79 −0.15 ● In the ZDV/3TC/NVP arm, there were
statistically significant changes in the
PHS score (P < 0.01) and a trend
toward statistically significant change
in the MHS score (P = 0.07).
MHS 45.72 (11.10) 12 months, 49.20 0.31
ZDV/3TC/NVP PHS 50.95 (11.37) 12 months, 56.73a 0.51
MHS 43.78 (9.92) 12 months, 48.22 0.45 ● There were no statistically significant
changes over time in the ZDV/3TC/NFV




therapy (PI- or NNRTI-based)
General
Health
NR NR N/A ● Although quality of life tended to
increase in both groups, no significant
differences were found during the















d4T/3TC/EFV PHS 50.5 48 weeks, 53.9 N/A ● PHS and MHS BL values were
comparable in all 3 treatment groups
(P = 0.883 and P = 0.937, respectively).MHS 46.9 48 weeks, 53.9 N/A
d4T/3TC/NVP PHS 51.0 48 weeks, 54.9 N/A ● No significant differences between
the 3 treatment groups in increases in
dimension scores.
MHS 46.7 48 weeks, 52.8 N/A ● After adjusting for all significantly
associated variables, the increase of
PHS was 4.6 for NVP, 4.8 for EFV and
3.8 for NVP + EFV (P = 0.790); the
adjusted increase of MHS was 6.1, 7.3
and 3.8, respectively (P = 0.093).
d4T/3TC/EFV/NVP PHS 50.9 48 weeks, 53.8 N/A
MHS 47.1 48 weeks, 51.0 N/A
Abbreviations: 3TC lamivudine, ABC abacavir, ARV antiretroviral, AZT zidovudine, BL baseline, CF cognitive functioning, d4T stavudine, ddI didanosine, DRV/r
darunavir/ritonavir, EFV efavirenz, ENF enfuvirtide, EWB emotional well-being, ETR etravirine, FGWB functional global well-being, FTC emtricitabine, HAART highly-
active antiretroviral therapy, IQR interquartile range, IR immediate release, MCS mental component score, MHS mental health summary, N/A not available,
NFV nelfinavir, NNRTI non-nucleoside reverse transcriptase inhibitor, NRTI nucleoside/nucleotide reverse transcriptase inhibitor, NS not significant, NVP nevirapine,
PCS physical component score, PHS physical health summary, PI protease inhibitor, PRC prolonged-release capsule, PRO patient-reported outcome, PWB physical
well-being, SD standard deviation, SWB social well-being, TDF tenofovir, ZDV zidovudine.
1184 weeks, or study discontinuation; 2Score ≥17 for men and ≥23 for women; 3Median (IQR); 4Mean change; 5Standard deviation estimated from IQR.
aSignificant change over time (P < 0.05); bSignificant change between groups (P < 0.05).
Simpson et al. Health and Quality of Life Outcomes 2013, 11:164 Page 13 of 15
http://www.hqlo.com/content/11/1/164
Simpson et al. Health and Quality of Life Outcomes 2013, 11:164 Page 14 of 15
http://www.hqlo.com/content/11/1/164instruments to measure the relevant constructs and to
identify the most useful batteries of instruments. Further-
more, new instruments may need to be developed to meet
future research needs.
Additional file
Additional file 1: Table A Search terms for identifying clinical
studies of NNRTIs with PRO instruments.
Competing interests
KAH and CLP are employees of UBC and GH is an employee of Evidera, both
of which received funding for this research from Pfizer. SH and MT are
employees of and have equity ownership in Pfizer. AK was an employee of
Pfizer at the time the study was conducted. KNS and AWW received funding
for this research from Pfizer.
Authors’ contributions
KAH and GH participated in the study conception and design, acquisition of
data, data analysis and interpretation, and manuscript writing. KNS, SH, MT,
CLP, and AWW participated in the study conception and design, data
interpretation, and manuscript writing. AK participated in the data
interpretation and manuscript writing. All authors read and approved the
final manuscript.
Author details
1Medical University of South Carolina, 171 Ashley Avenue, Charleston, SC
29425, USA. 2UBC: An Express Scripts Company, 185 Dorval Ave, Suite 500,
Dorval, QC H9S 5J9, Canada. 3Evidera, 7101 Wisconsin Avenue, Suite 600,
Bethesda, MD 20814, USA. 4Pfizer Inc., 558 Eastern Point Road, Groton, CT
06340, USA. 5Pharmerit, 4350 East West Highway, Suite 430, Bethesda, MD
20814, USA. 6UBC: An Express Scripts Company, 430 Bedford Street,
Lexington, MA 02420, USA. 7Johns Hopkins Bloomberg School of Public
Health, 615 North Wolfe Street, Baltimore, MD 21205, USA.
Received: 8 November 2012 Accepted: 5 September 2013
Published: 3 October 2013
References
1. Clumeck N, Pozniak A, Raffi F: European AIDS Clinical Society (EACS)
guidelines for the clinical management and treatment of HIV-infected
adults. HIV Med 2008, 9(2):65–71.
2. Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S,
Cahn P, Fischl MA, Gatell JM, Hirsch MS, Jacobsen DM, Montaner JS,
Richman DD, Yeni PG, Volberding PA: Antiretroviral treatment of adult HIV
infection: 2008 recommendations of the International AIDS Society-USA
panel. JAMA 2008, 300(5):555–570.
3. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents:
Guidelines for the use of antiretroviral agents in HIV-1-infected adults and
adolescents. Department of Health and Human Services; 2011:1–166.
http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
4. Food and Drug Administration: Guidance for industry on patient-reported
outcome measures: use in medical product development to support
labeling claims. Fed Regist 2009, 74(235):65132–65133.
5. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents:
Guidelines for the use of antiretroviral agents in HIV-1-infected adults and
adolescents. Department of Health and Human Services; 2008:1–139. http://
www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
6.1 European AIDS Clinical Society (EACS): Guidelines for the clinical
management and treatment of HIV infected adults in Europe. Version 6.1
EACS; 2012. http://www.eacsociety.org/Portals/0/files/pdf%20files/
EacsGuidelines-v6.1-2edition.pdf.
7. Dabaghzadeh F, Ghaeli P, Khalili H, Alimadadi A, Jafari S, Akhondzadeh S,
Khazaeipour Z: Cyproheptadine for prevention of neuropsychiatric
adverse effects of efavirenz: a randomized clinical trial. AIDS Patient Care
STDS 2013, 27(3):146–154.
8. Bucciardini R, D'Ettorre G, Baroncelli S, Ceccarelli G, Parruti G, Weimer LE,
Fragola V, Galluzzo CM, Pirillo MF, Lucattini S, Bellagamba R, Francisci D,Ladisa N, Degli Antoni A, Guaraldi G, Manconi PE, Vullo V, Preziosi R, Cirioni
O, Verucchi G, Floridia M: Virological failure at one year in triple-class
experienced patients switching to raltegravir-based regimens is not
predicted by baseline factors. Int J STD AIDS 2012, 23(7):459–463.
9. Lake JE, McComsey GA, Hulgan TM, Wanke CA, Mangili A, Walmsley SL,
Boger MS, Turner RR, McCreath HE, Currier JS: A randomized trial of
Raltegravir replacement for protease inhibitor or non-nucleoside reverse
transcriptase inhibitor in HIV-infected women with lipohypertrophy.
AIDS Patient Care STDS 2012, 26(9):532–540.
10. Mosam A, Shaik F, Uldrick TS, Esterhuizen T, Friedland GH, Scadden DT,
Aboobaker J, Coovadia HM: A randomized controlled trial of highly active
antiretroviral therapy versus highly active antiretroviral therapy and
chemotherapy in therapy-naive patients with HIV-associated Kaposi
sarcoma in South Africa. J Acquir Immune Defic Syndr 2012, 60(2):150–157.
11. Cooper V, Moyle GJ, Fisher M, Reilly G, Ewan J, Liu HC, Horne R: Beliefs
about antiretroviral therapy, treatment adherence and quality of life in a
48-week randomised study of continuation of zidovudine/lamivudine or
switch to tenofovir DF/emtricitabine, each with efavirenz. AIDS Care 2011,
23(6):705–713.
12. Nguyen A, Calmy A, Delhumeau C, Mercier I, Cavassini M, Mello AF, Elzi L,
Rauch A, Bernasconi E, Schmid P, Hirschel B: A randomized cross-over
study to compare raltegravir and efavirenz (SWITCH-ER study). AIDS 2011,
25(12):1481–1487.
13. Nguyen A, Calmy A, Delhumeau C, Mercier IK, Cavassini M, Fayet-Mello A, Elzi L,
Genne D, Rauch A, Bernasconi E, Hirschel B: A randomized crossover study to
compare efavirenz and etravirine treatment. AIDS 2011, 25(1):57–63.
14. Campo RE, Cohen C, Grimm K, Shangguan T, Maa J, Seekins D: Switch from
protease inhibitor- to efavirenz-based antiretroviral therapy improves
quality of life, treatment satisfaction and adherence with low rates of
virological failure in virologically suppressed patients. Int J STD AIDS 2010,
21(3):166–171.
15. Cella D, Gilet H, Viala-Danten M, Peeters K, Dubois D, Martin S: Effects of
etravirine versus placebo on health-related quality of life in treatment-
experienced HIV patients as measured by the functional assessment of
human immunodeficiency virus infection (FAHI) questionnaire in the
DUET trials. HIV Clin Trials 2010, 11(1):18–27.
16. Cooper V, Horne R, Gellaitry G, Vrijens B, Lange AC, Fisher M, White D: The
impact of once-nightly versus twice-daily dosing and baseline beliefs
about HAART on adherence to efavirenz-based HAART over 48 weeks:
the NOCTE study. J Acquir Immune Defic Syndr 2010, 53(3):369–377.
17. Cooper DA, Heera J, Goodrich J, Tawadrous M, Saag M, Dejesus E, Clumeck
N, Walmsley S, Ting N, Coakley E, Reeves JD, Reyes-Teran G, Westby M, Van
Der Ryst E, Ive P, Mohapi L, Mingrone H, Horban A, Hackman F, Sullivan J,
Mayer H: Maraviroc versus efavirenz, both in combination with
zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects
with CCR5-tropic HIV-1 infection. J Infect Dis 2010, 201(6):803–813.
18. Regnault A, Marfatia S, Louie M, Mear I, Meunier J, Viala-Danten M: Satisfactory
cross-cultural validity of the ACTG symptom distress module in HIV-1-
infected antiretroviral-naive patients. Clinical trials 2009, 6(6):574–584.
19. Hodder SL, Mounzer K, Dejesus E, Ebrahimi R, Grimm K, Esker S, Ecker J,
Farajallah A, Flaherty JF: Patient-reported outcomes in virologically
suppressed, HIV-1-Infected subjects after switching to a simplified,
single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
AIDS Patient Care STDS 2010, 24(2):87–96.
20. DeJesus E, Young B, Morales-Ramirez JO, Sloan L, Ward DJ, Flaherty JF,
Ebrahimi R, Maa JF, Reilly K, Ecker J, McColl D, Seekins D, Farajallah A:
Simplification of antiretroviral therapy to a single-tablet regimen
consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate
versus unmodified antiretroviral therapy in virologically suppressed HIV-
1-infected patients. J Acquir Immune Defic Syndr 2009, 51(2):163–174.
21. Potard V, Chassany O, Lavignon M, Costagliola D, Spire B: Better health-related
quality of life after switching from a virologically effective regimen to a
regimen containing efavirenz or nevirapine. AIDS Care 2010, 22(1):54–61.
22. Clifford DB, Evans S, Yang Y, Acosta EP, Ribaudo H, Gulick RM: Long-term
impact of efavirenz on neuropsychological performance and symptoms in
HIV-infected individuals (ACTG 5097s). HIV Clin Trials 2009,
10(6):343–355.
23. Gutierrez-Valencia A, Viciana P, Palacios R, Ruiz-Valderas R, Lozano F, Terron
A, Rivero A, Lopez-Cortes LF: Stepped-dose versus full-dose efavirenz for
HIV infection and neuropsychiatric adverse events: a randomized trial.
Ann Intern Med 2009, 151(3):149–156.
Simpson et al. Health and Quality of Life Outcomes 2013, 11:164 Page 15 of 15
http://www.hqlo.com/content/11/1/16424. Jayaweera D, Dejesus E, Nguyen KL, Grimm K, Butcher D, Seekins DW:
Virologic suppression, treatment adherence, and improved quality of life
on a once-daily efavirenz-based regimen in treatment-Naive HIV-1-
infected patients over 96 weeks. HIV Clin Trials 2009, 10(6):375–384.
25. Boyle BA, Jayaweera D, Witt MD, Grimm K, Maa JF, Seekins DW:
Randomization to once-daily stavudine extended release/lamivudine/
efavirenz versus a more frequent regimen improves adherence while
maintaining viral suppression. HIV Clin Trials 2008, 9(3):164–176.
26. DeJesus E, Ruane P, McDonald C, Garcia F, Sharma S, Corales R, Ravishankar J,
Khanlou H, Shamblaw D, Ecker J, Ebrahimi R, Flaherty J: Impact of switching
virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose
zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil
fumarate/emtricitabine. HIV Clin Trials 2008, 9(2):103–114.
27. Bucciardini R, Fragola V, Massella M, Polizzi C, Mirra M, Goodall R, Carey D,
Hudson F, Zajdenverg R, Floridia M: Health-related quality of life
outcomes in HIV-infected patients starting different combination
regimens in a randomized multinational trial: the INITIO-QoL substudy.
AIDS Res Hum Retroviruses 2007, 23(10):1215–1222.
28. Lafaurie M, Collin F, Bentata M, Garre M, Leport C, Levy Y, Goujard C, Chene
G, Molina JM: Switch from zidovudine- to non-zidovudine-containing
regimens is associated with modest haematological improvement and
no obvious clinical benefit: a substudy of the ANRS 099 ALIZE trial.
J Antimicrob Chemother 2008, 62(5):1122–1129.
29. Journot V, Chene G, De Castro N, Rancinan C, Cassuto JP, Allard C, Vilde JL,
Sobel A, Garre M, Molina JM: Use of efavirenz is not associated with a
higher risk of depressive disorders: a substudy of the randomized
clinical trial ALIZE-ANRS 099. Clin Infect Dis 2006, 42(12):1790–1799.
30. Portsmouth SD, Osorio J, McCormick K, Gazzard BG, Moyle GJ: Better
maintained adherence on switching from twice-daily to once-daily
therapy for HIV: a 24-week randomized trial of treatment simplification
using stavudine prolonged-release capsules. HIV Med 2005, 6(3):185–190.
31. Casado A, Badia X, Consiglio E, Ferrer E, Gonzalez A, Pedrol E, Gatell JM,
Azuaje C, Llibre JM, Aranda M, Barrufet P, Martinez-Lacasa J, Podzamczer D,
Team CS: Health-related quality of life in HIV-infected naive patients
treated with nelfinavir or nevirapine associated with ZDV/3TC (the
COMBINE-QoL substudy). HIV Clin Trials 2004, 5(3):132–139.
32. Negredo E, Molto J, Munoz-Moreno JA, Pedrol E, Ribera E, Viciana P,
Galindos MJ, Miralles C, Burger D, Rodriguez Fumaz C, Puig J, Gel S,
Rodriguez E, Videla S, Ruiz L, Clotet B: Safety and efficacy of once-daily
didanosine, tenofovir and nevirapine as a simplification antiretroviral
approach. Antiviral therapy 2004, 9(3):335–342.
33. van Leth F, Conway B, Laplume H, Martin D, Fisher M, Jelaska A, Wit FW,
Lange JM, group NNs: Quality of life in patients treated with first-line
antiretroviral therapy containing nevirapine and/or efavirenz.
Antiviral therapy 2004, 9(5):721–728.
34. Kallianpur AR, Hulgan T, Canter JA, Ritchie MD, Haines JL, Robbins GK,
Shafer RW, Clifford DB, Haas DW: Hemochromatosis (HFE) gene mutations
and peripheral neuropathy during antiretroviral therapy. AIDS 2006,
20(11):1503–1513.
35. Maggiolo F, Ravasio L, Ripamonti D, Gregis G, Quinzan G, Arici C, Airoldi M,
Suter F: Similar adherence rates favor different virologic outcomes for
patients treated with nonnucleoside analogues or protease inhibitors.
Clin Infect Dis 2005, 40(1):158–163.
36. Santos J, Palacios R, Lopez M, Galvez MC, Lozano F, de la Torre J, Rios MJ,
Lopez-Cortes LF, Rivero A, Torres-Tortosa M, Grupo Andaluz para el Estudio
de las Enfermedades I: Simplicity and efficacy of a once-daily
antiretroviral regimen with didanosine, lamivudine, and efavirenz in
naive patients: the VESD study. HIV Clin Trials 2005, 6(6):320–328.
37. Martinez-Picado J, Negredo E, Ruiz L, Shintani A, Fumaz CR, Zala C, Domingo P,
Vilaro J, Llibre JM, Viciana P, Hertogs K, Boucher C, D'Aquila RT, Clotet B, Team
SS: Alternation of antiretroviral drug regimens for HIV infection. A
randomized, controlled trial. Ann Intern Med 2003, 139(2):81–89.38. Centers for AIDS Research (CFAR) Network of Integrated Clinical Systems
(CNICS): CNICS Data Elements http://www.uab.edu/cnics/data-core/cnics-
data-elements.
39. Kozak MS, Mugavero MJ, Ye J, Aban I, Lawrence ST, Nevin CR, Raper JL,
McCullumsmith C, Schumacher JE, Crane HM, Kitahata MM, Saag MS, Willig
JH: Patient reported outcomes in routine care: advancing data capture
for HIV cohort research. Clin Infect Dis 2012, 54(1):141–147.
doi:10.1186/1477-7525-11-164
Cite this article as: Simpson et al.: Patient reported outcome
instruments used in clinical trials of HIV-infected adults on NNRTI-based
therapy: a 10-year review. Health and Quality of Life Outcomes
2013 11:164.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
